| Name | Repaglinide |
| Description | Repaglinide (AG-EE 623ZW) is a benzoic acid derivative that stimulates insulin secretion from the pancreas and is used in the therapy of type 2 diabetes. Repaglinide has been linked to rare instances of clinically apparent acute liver injury. |
| In vitro | Repaglinide binds to NCS proteins in a calcium-dependent manner, but does not bind to CAM or S100 proteins.Repaglinide tightly binds to CCaMK and PpCaMK in a calcium-dependent manner, antagonizing the regulatory function of the structural domains, with IC 50 values of 55 mM and 4 mM for the CCaMK and PpCaMK domains.Repaglinide binds to CCaMK and PpCaMK domains with low affinity (K(D) = 59 nM) to bind SUR1 alone, but binds SUR1 with high affinity to co-express with Kir6.2, increasing it approximately 150-fold.Repaglinide antagonizes the inhibitory effect of restoring protein in the retinal kinase assay, with an IC50 value of 400 mM.Repaglinide also antagonizes the inhibitory effect of restoring protein in the retinal kinase assay, with an IC50 value of 400 mM. |
| In vivo | Repaglinide binds to NCS proteins in a calcium-dependent manner, but does not bind to CAM or S100 proteins.Repaglinide tightly binds to CCaMK and PpCaMK in a calcium-dependent manner, antagonizing the regulatory function of the structural domains, with IC 50 values of 55 mM and 4 mM for the CCaMK and PpCaMK domains.Repaglinide binds to CCaMK and PpCaMK domains with low affinity (K(D) = 59 nM) to bind SUR1 alone, but binds SUR1 with high affinity to co-express with Kir6.2, increasing it approximately 150-fold.Repaglinide antagonizes the inhibitory effect of restoring protein in the retinal kinase assay, with an IC50 value of 400 mM.Repaglinide also antagonizes the inhibitory effect of restoring protein in the retinal kinase assay, with an IC50 value of 400 mM. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+90% Corn oil : 10 mg/mL (22.1 mM), Solution.
Ethanol : 84 mg/mL (185.6 mM), Sonication is recommended.
DMSO : 250 mg/mL (552.38 mM), Sonication is recommended.
10% DMSO+90% Saline : < 10 mg/mL (22.1 mM), Lower concentrations may be soluble, but exact solubility limit is unknown.
H2O : < 1 mg/mL (insoluble or slightly soluble)
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 10 mg/mL (22.1 mM), Suspension.
10% DMSO+90% (20% SBE-β-CD in Saline) : < 10 mg/mL (22.1 mM), Lower concentrations may be soluble, but exact solubility limit is unknown.
|
| Keywords | type-2 | secretagogue | Repaglinide | PPARγ | PotassiumChannel | Potassium Channel | mellitus. | insulin | Inhibitor | inhibit | diabetes | CMBA | carbamoylmethyl | benzoic | acid |
| Inhibitors Related | Rosiglitazone | Uridine 5'-monophosphate disodium salt | Daidzein | 1,8-Cineole | Tetraethylammonium bromide | Magnesium acetate tetrahydrate | Maltitol | Ursodeoxycholic acid | Chenodeoxycholic acid | 2,3-Butanediol | NPC 15199 | Cloxiquine |
| Related Compound Libraries | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Pain-Related Compound Library | Membrane Protein-targeted Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | FDA-Approved Drug Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Ion Channel Targeted Library | Anti-Cancer Drug Library |
United States
